Recommendation of the President – Kinpeygo (budesonide)
On 26 August 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 89/2024 on the evaluation of the drug Kinpeygo (budesonide) under the drug program “Treatment of patients with primary IgA nephropathy (ICD 10: N02.8)”